Product Regulation and Metrology Bill [HL]

Baroness Brinton Excerpts

Report stage
Wednesday 26th February 2025 Lords Chamber

[Baroness Brinton (LD)]

My Lords, I declare my interest as a vice-chair of the All-Party Parliamentary Group on Fire Safety and Rescue. In that context, I support Amendment 7 in the name of the noble Lord, Lord Foster, and endorse his comments on lithium batteries, given that I had similar amendments in Committee. Importantly, the product is not included, and I hope the Government will be able to take note of that and help.

I also support Amendment 9, in the name of the noble Lord, Lord Fox. I think I was the first person at Second Reading to raise the question of criminal issues. The amendment helps us to get to a solution that provides scrutiny. Early scrutiny by Parliament is much stronger than the affirmative procedure.

I continue to support the campaign of the noble Baroness, Lady Bennett, which is encapsulated in her Amendment 26. I also support the powerful example given to us by the noble Baroness, Lady Freeman. However, I disagree, in that, in my view, tampons should be as well-regulated as blusher. They should be deemed to be a medical device, for all the biocidal reasons that the noble Baroness, Lady Bennett, explained —and I will not rehearse those. I remind your Lordships’ House that paragraph 9 of the schedule at the end of the Bill removes medicines and medical devices as defined in the Medicines and Medical Devices Act. Unfortunately, with period and incontinence products there are health issues. If they are not defined under that Act, there needs to be some way of recognising that they have an impact on individual health. I therefore support Amendment 26 and hope that the Government will listen to that as well.

I should also point out that there is more information on the government website about the correct taxation of period products and incontinence products than there is elsewhere on the health issues.

[Lord Sharpe of Epsom (Con)]

My Lords, I thank all noble Lords for their amendments in this instructive and interesting debate. I am a little wary about speaking after finding out how much plastic is in our brains, because that is obviously potentially to invite unfavourable comment.

I shall speak sympathetically to my noble friend Lord Lansley’s Amendments 3 and 12. One of the many problems that we have already discussed at some length, now and in Committee, is the vagueness of the Bill as drafted. That lack of clarity creates significant uncertainty for both businesses and consumers, so I thank my noble friend for his contributions. His amendments offer important suggestions that could help to address some of these issues, particularly by expanding the definition of safety and, indeed, providing a definition of safety.

As technology continues to develop, it is critical that we recognise that our understanding of what constitutes safety must also evolve. My noble friend’s amendments reflect that forward-thinking approach, acknowledge that new technologies and innovations may require updates to safety standards over time and, by expanding the definition, would ensure that the legislation remained flexible and adaptable, allowing for future growth and innovation without sacrificing safety. As my noble friend pointed out, different language suggests different outcomes, so I hope the Minister will be able to address that in answering my noble friend’s questions. We believe that these amendments provide much-needed clarity in areas where the Bill could have been more precise, and we are grateful to my noble friend Lord Lansley for bringing this issue into sharper focus.

Amendment 7 in the name of the noble Lords, Lord Foster of Bath and Lord Fox, and my noble friend Lord Lindsay—who, as the noble Lord, Lord Foster, pointed out, is president of the Chartered Trading Standards Institute—has significant merit. The noble Lord, Lord Foster, made a persuasive case, with some alarming statistics and illustrations. Consumers should have confidence that the products they buy, whether from a high street store or an online platform, are safe and, if things go wrong, that there is a clear route to accountability. By allowing regulations to extend liability to online marketplaces and ensuring the proper disclosure of evidence in claims for compensation, this amendment would strengthen consumer rights and help to create a fairer system. We will return at a later stage to the definitions of online marketplaces.

Amendment 9 in the name of the noble Lord, Lord Fox, would also help to do things better. I should remind the noble Lord that, in effect, it would mean more consultation. I am reluctant to remind the noble Baroness, Lady Finlay of Llandaff, of this, but the DPRRC, on which she sits, said in its most recent report on 21 February that

“consultation is not a substitute for Parliamentary scrutiny”.

However, I recognise that, in pointing that out, I am probably flogging something of a dead horse.

I turn to Amendment 26 and the other amendments in the name of the noble Baroness, Lady Bennett, which were spoken to—again, very persuasively—by the noble Baronesses, Lady Freeman and Lady Smith. These amendments address an important issue: ensuring that period products meet high safety standards while also considering their environmental impact. Given that these products are used by millions of women and girls, often over a lifetime, it is only right that their safety, composition and labelling are subject to clear and effective regulation; the list of organisations quoted by the noble Baroness, Lady Bennett, is illustrative of the interest in this particular area.

The safety and regulation of period products is a matter of both public health and consumer protection, so ensuring that individuals can make informed choices about the products they use is obviously essential. Amendment 26 seeks to introduce clear and necessary provisions for testing, marking and risk information, reflecting the need for greater transparency and oversight in this area. By addressing both single-use and reusable products, it acknowledges the evolving nature of the market while prioritising safety and well-being. We ask the Government to take further consideration and to carry out additional study on this important area—and, indeed, to expand it to some of the other areas that the noble Baroness mentioned, such as the formaldehyde that is present in non-iron shirts. Of course, one of the other uses of formaldehyde is to preserve dead bodies; I am not sure what that tells us about our sartorial choices, but there we are.

As the market for period products continues to evolve—particularly with increasing interest in reusable products—it is obviously essential that any regulation stays relevant and up to date, so we expect to return to this issue in future health-related Bills. The noble Baroness, Lady Brinton, made some very good points about the fact that these products should be treated as medical devices; those deserve to be explored further. It is crucial that we continue to monitor and adapt the regulation of these products in order to ensure that public health and consumer protection are maintained.

--- Later in debate ---

[Lord Lansley (Con)]

My Lords, I know that we are all most grateful to the Minister for what I thought was an extremely helpful response to these important and interesting issues that we have debated in this group.

For my part, in relation to Amendment 3 and the use of “safe”, I agree with the noble and learned Lord, Lord Hope of Craighead, that the use of “safe” in a Bill that is intended to ensure that products are safe would be most helpful. He will note that Amendment 12 defines “safe” in a similar way—not precisely the same as the Consumer Protection Act does at present—as meaning

“that there is no risk, or no risk apart from one reduced to a minimum”,

so it is not to say that a product has no risk.

The Minister is right that this is about product safety—I completely agree—and identification of risk. I think where the noble Lord, Lord Fox, is coming from is on understanding how risk is identified and so on. I have some sympathy with the points he makes on Amendment 9, but I find it entirely arguable whether the definition of safe in the present legislation and the definition in this Bill are very close to one another. I slightly rest my argument for the Minister, and perhaps his officials, to think about: would it not therefore be helpful to include a provision in Clause 1 saying that products should be safe, meaning that there is no risk or a risk that is reduced to a minimum or mitigated, since that is what the Government intend to do? They are intending that people should be able to say that products are safe; they have just chosen to take the word out of statute. I think it would be rather helpful to put it back in. I rest my case there and will not press it further.

On Amendment 28, the Minister very helpfully said more than he said in Committee, although it was not inconsistent with what he said then. In particular, he gave us a timetable, which, of course, is immensely helpful. It is quite a long one and goes to the end of 2026, but I know how these things grind through the machines. He will find that there is a pressing need for a review of the product liability directive, especially in relation to online marketplaces, not least because the Law Commission identified this as an area for reform of the law in its 14th work programme—and that was something like three years ago. We are not only well out of date but well beyond the point at which a need for action on product liability had been identified. I hope we might keep pressing, alongside the Minister, for the progress that needs to be made in the consultation and subsequent legislation.

I have one more point. On Amendment 26 and the question of period products, I say to the noble Baroness, Lady Brinton, that I was wondering about this. I have checked, but if I understand the position correctly, period products are not regarded as medical devices; they are regarded as consumer products. Incontinence pants—disposable body-worn pads—are treated as medical devices by the MHRA. That is a distinction without a difference, one that I do not understand. I think that period products are regarded as medical devices by the Food and Drug Administration in America. Of course, we follow where the European Union’s general product safety regulation has been and the definitions it has put into its own regulations. One area that Ministers might think about is whether it would be more appropriate for these products to be regarded as medical devices and brought under the scope of the regulations.

[Baroness Brinton (LD)]

I have a very minor and technical point, but I referred to products and not just pants, because the whole line of products has changed. I do not believe that either period or incontinence pants are covered. That is my concern but I thank the noble Lord for his point.

[Lord Lansley (Con)]

I will not argue but there is probably a good basis for thinking about whether—rather than including them in the Bill, I say with great respect to the proposers of Amendment 26—it would be more appropriate to revisit the question of having them covered under the Medicines and Medical Devices Act 2021. I will leave it there.

On the basis of the point that we have reached with Amendment 3, and that the Minister will have heard, at the very least, the argument for the consumer and communications benefit of saying that we are aiming to make products safe, I will leave it in his capable hands and not seek to press this. I beg leave to withdraw Amendment 3.